| Ytd | 0.26% | |
| 1y | 93.03% |
| Open | 34.33 | Prev Close | 33.89 | Low | 34.06 | High | 35.40 | Mkt Cap | 4.11B |
| Vol | 867.67K | Avg Vol | 1.29M | EPS | -1.78 | P/E | N/A | Forward P/E | -27.63 |
| Beta | 0.08 | Short Ratio | 7.09 | Inst. Own | 106.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 32.68 | 200-d Avg | 33.56 | 1yr Est | 49.46 |
NAMS News
NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperf
US stocks, including Monster Beverage Corp, rose on Friday. Monster Beverage reported better-than-ex
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.40) per share which beat the anal
Guggenheim analyst Debjit Chattopadhyay maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and rais
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperf
-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26
Stifel analyst James Condulis maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raise
Goldman Sachs analyst Asad Haider maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperf
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and rais
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.61) per share which missed the an
HC Wainwright & Co. analyst Joseph Pantginis assumes NewAmsterdam Pharma Co (NASDAQ:NAMS) wit
Citigroup analyst Geoff Meacham maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and rai
Wells Fargo analyst Yanan Zhu initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a O
The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperf
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.15) per share which beat the anal
-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217
https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/
Goldman Sachs analyst Asad Haider initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) wit
Citigroup analyst Geoff Meacham initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company rep
Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Tech
Gainers
On Tuesday, 89 companies set new 52-week lows.